人工智能在全球人群中基于MRI检测和筛查前列腺癌:SCARLET-1研究
SCARLET-1回顾性验证研究纳入22,445例检查,评估AI系统在外部诊断和筛查数据集中检测Gleason分级分组≥2前列腺癌的性能。外部AUC为0.84-0.89,与放射科医生读片的一致率83.0%-87.9%,均满足预设的可互换性标准;但不同站点间性能差异显著,28%站点AUC<0.80。
要点
- AI在外部诊断和筛查数据集中检测GG≥2前列腺癌的AUC为0.84-0.89,与放射科读片相当。
- AI与标准诊断的一致率为83.0%-87.9%,在所有数据集中满足预设可互换性标准。
- 站点间性能差异显著:28%站点AUC<0.80,32%站点AUC≥0.90,图像质量影响AUC(0.78-0.88)。
诊断标准与关键数值
- 外部测试AUC:PRIME为0.86(95% CI: 0.83, 0.90),STHLM3-MRI为0.89(95% CI: 0.86, 0.92),IP1-PROSTAGRAM为0.84(95% CI: 0.70, 0.95)。
- 主要结局一致率:PRIME为83.0%(395/476;调整95% CI: 78.8%, 87.0%),STHLM3-MRI为87.9%(974/1108;调整95% CI: 85.6%, 90.3%),IP1-PROSTAGRAM为87.7%(342/390;调整95% CI: 83.6%, 91.5%),均满足预设可互换性标准。
- 亚组性能在年龄、风险、癌症位置和种族间一致(平均ΔAUC为0.02),但25个站点间差异显著(28%站点AUC<0.80;32%站点AUC≥0.90),且随图像质量变化(AUC 0.78-0.88)。
局限性
- 回顾性验证研究设计。
- 站点间性能差异显著(28%站点AUC<0.80)。
- 图像质量影响AUC(0.78-0.88)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Artificial intelligence (AI) systems have demonstrated non-inferiority to radiologists for prostate cancer detection on MRI, but evidence in global diagnostic and population-based screening settings remains limited. Purpose To determine whether an AI system can achieve diagnostic performance comparable to radiology readings for detecting Gleason grade group ≥2 prostate cancer on MRI in external diagnostic and screening datasets. Materials and Methods In the SCARLET-1 retrospective validation study, prostate MRIs from adults with suspected prostate cancer (January 2012-October 2024) were used to evaluate an AI system, with external testing in diagnostic (PRIME) and organized screening settings (STHLM3-MRI and IP1-PROSTAGRAM). The primary outcome was agreement between AI assessments and standard-of-care diagnoses of Gleason grade group ≥2 cancer, with diagnostic interchangeability defined relative to the estimated agreement of an average radiologist. Secondary outcomes included area under the receiver operating characteristic curve (AUC) across datasets and subgroups. Results 22,445 examinations (21,252 male patients; median age, 66 years [IQR 60-71]) were included: 20,471 prostate MRI examinations (19,278 patients; 26 cities, 14 countries) for AI training and internal testing, and 1974 patients (20 external cities, 12 countries) for external testing. External AUCs were 0.86 (95% CI: 0.83, 0.90) in PRIME, 0.89 (95% CI: 0.86, 0.92) in STHLM3-MRI, and 0.84 (95% CI: 0.70, 0.95) in IP1-PROSTAGRAM. The primary outcome was 83.0% (395 of 476; adjusted 95% CI: 78.8%, 87.0%), 87.9% (974 of 1108; adjusted 95% CI: 85.6%, 90.3%), and 87.7% (342 of 390; adjusted 95% CI: 83.6%, 91.5%), respectively, meeting prespecified interchangeability criteria in all datasets. Subgroup performance was consistent across age, risk, cancer location and ethnicity (mean ΔAUC, 0.02), but varied substantially across 25 sites (28% with AUC<0.80; 32% with AUC ≥0.90) and by image quality (AUC, 0.78-0.88). Conclusion AI demonstrated diagnostic performance comparable to that of radiology readings across external diagnostic and screening datasets. © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license.
引用
- Saha A, Bosma JS, Twilt JJ, et al. Artificial Intelligence for Prostate Cancer Detection and Screening on MRI in Global Populations: The SCARLET-1 Study. Radiology. 2026. PMID: 42867371. doi:10.1148/radiol.262081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。